It’s hard to get excited about a modified chemotherapy drug in an era of personalized medicine, checkpoint inhibitors, and CAR-T immunotherapies.
But it would be a mistake to not embrace a potential advance in this field, given the degree to which oncologists (and even some other specialties, such as rheumatology) still rely on this class of drugs.
Based in the Netherlands, Modra Pharmaceuticals is taking aim at a group of chemotherapy agents known as taxanes, which include paclitaxel (Taxol) and docetaxel (Taxotere). Despite their widespread use, taxanes are poorly soluble — a characteristic that has forever restricted them to intravenous (IV) administration.
Read more here